Leukemia Trial Results
- Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia
(Posted: 01/24/2007) - Positive results of a phase III cancer clinical trial in an uncommon form of leukemia were released today. The results showed that adult patients with previously untreated acute promyelocytic leukemia who had standard chemotherapy to induce remission of their disease, and then received the chemotherapy drug arsenic trioxide to maintain remission, had a significantly better event-free survival (more patients free of leukemia) and better overall survival than those who received only standard chemotherapy. The trial was sponsored by the NCI, and was led by one of its Cooperative Clinical Trials Groups -- the Cancer and Leukemia Group B.